452296-79-6

Usage

Uses

Used in Pharmaceutical Industry:
4,7-DIMETHOXY-1H-PYRROLO[2,3-C]PYRIDINE is used as a building block for the synthesis of pharmaceuticals. Its structure and properties make it a valuable intermediate in the development of new drugs, contributing to the discovery of novel therapeutic agents with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical sector, 4,7-DIMETHOXY-1H-PYRROLO[2,3-C]PYRIDINE serves as a key component in the synthesis of agrochemicals. Its versatile nature allows for the creation of a wide range of analogs and derivatives with potential applications in crop protection, enhancing agricultural productivity and sustainability.
Used in Research and Development:
4,7-DIMETHOXY-1H-PYRROLO[2,3-C]PYRIDINE is utilized in research and development activities related to drug discovery and crop protection. Its chemical structure and functional groups make it a promising candidate for exploring new organic reactions and creating innovative compounds with valuable biological activities.
Overall, 4,7-DIMETHOXY-1H-PYRROLO[2,3-C]PYRIDINE's unique structure and properties position it as a versatile and valuable compound in various industries, particularly in the development of pharmaceuticals and agrochemicals, as well as in research and development activities.

InChI:InChI=1/C9H10N2O2/c1-12-7-5-11-9(13-2)8-6(7)3-4-10-8/h3-5,10H,1-2H3

Upstream product

• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 124-41-4 sodium methylate 
• 425380-38-7 4-bromo-7-chloro-3a,7a-dihydro-1H-pyrrolo[2,3-c]pyridine 

Downstream Products

• 446284-32-8 7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine 
• 1392514-37-2 C₃₁H₂₈ClN₇O₄S 
• 1392514-36-1 C₂₁H₁₈ClN₅O₄S 
• 1392514-39-4 C₂₅H₂₄ClN₇O₄ 
• 864953-39-9 1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl hydrogen phosphate 

Relevant academic research and scientific papers

Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement

With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive, yet underexploited therapeutic approach with implications for salvage and preexposure prophylactic regimens, as well as topical microbicides. Using the combination of a field-derived bioactive conformation template to perform virtual screening and iterative bioisosteric replacements, coupled with in silico predictions of absorption, distribution, metabolism, and excretion, we have identified new leads for HIV-1 entry inhibitors.

Prodrugs of piperazine and substituted piperidine antiviral agents

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.